Comparative analysis of the duration of sporadic forms of motor neuron disease in the Republic of Sakha (Yakutia)
https://doi.org/10.25789/YMJ.2021.76.19
Abstract
The article describes a study of the duration of the disease in patients with different forms of motor neuron disease (MND) in the Republic of Sakha (Yakutia), depending on ethnicity, age and gender. The obtained results correlate with the data of researchers in the world and depend on the combined or isolated lesion of the motor neuron.
About the Authors
T. K. Davydova
YSC CMP
Russian Federation
Russian Federation
Davydova Tatiana Kimovna – Candidate of Medical Sciences, associate researcher, Director of the Center for Neurodegenerative Diseases, Head of the lab.
S. S. Shadrina
NEFU named after M.K. Ammosov
Russian Federation
Russian Federation
Shadrina Svetlana Semyonovna – associate researcher, scientific-research lab.
M. A. Varlamova
YSC CMP
Russian Federation
Russian Federation
Varlamova Marina Alekseevna – research associate
N. A. Schneider
Federal State Budgetary Institution "V.M. Bekhterev National Medical Research Center of Psychiatry and Neurology" of the Ministry of Health of Russia; Krasnoyarsk State Medical University named after V.F. Voino-Yasenetsky
Russian Federation
Russian Federation
Schneider Natalia Alekseevna – MD, Prof., associate researcher of the Center for Personalized Psychiatry and Neurology; associate researcher
St. Petersburg; Krasnoyarsk
P. S. Goncharova
FSBI "National Medical Center"
Russian Federation
Russian Federation
Goncharova Polina Sergeevna –neurologist-resident of the Center for Personalized Psychiatry and Neurology
References
1. Davydova TK, Nikolaeva TYa, Okoneshnikova LT. Comparative analysis of sporadic cases and familial forms of progressive muscle atrophy over a 30-year period (1986-2016) in the Republic of Sakha (Yakutia). Yakut Medical Journal. 2018; 4 (64): 110-113. DOI 10.25789/YMJ.2018.64.34.
2. Levitsky GN. Amyotrophic lateral sclerosis: treatment and theoretical issues. M: Practical Medicine, 2010; 562
3. Davydova TK, Shadrina SS, Schneider NA, et al. Disorders of the emotional sphere in patients with motor neuron disease in the Republic of Sakha (Yakutia). Yakut Medical Journal. 2021; 1 (73): 110-113. DOI 10.25789/YMJ.2021.73.03
4. Hondkarian OA, Bunin TL, Zavalishin IA. Amyotrophic lateral sclerosis. M: Medicine. 1978: 264.
5. Van den Berg-Vos RM, Visser J, Kalmijn S, et al. A long-term prospective study of the natural course of sporadic adult-onset lower motor neuron syndromes Arch Neurol. 2009; 66(6): 751-757. DOI:10.1001/archneurol.2009.91
6. Juntas Morales R, Pageot N, Taieb G, et al. Adult-onset spinal muscular atrophy: An update. Rev Neurol (Paris). 2017; 73(5): 308-319. DOI:10.1016/j.neurol.2017.03.015
7. Yang X, Y. Ji, Wang W, et al. Amyotrophic Lateral Sclerosis: Molecular Mechanisms, Biomarkers, and Therapeutic Strategies Antioxidants (Basel). 2021; 10(7): 1012. DOI: 10.3390/antiox10071012
8. Matsubara T, Oda M, Takahashiet T, et al. Amyotrophic lateral sclerosis of long clinical course clinically presenting with progressive muscular atrophy. Neuropathology. 2019; Feb. 39(1): 47-53. DOI: 10.1111/neup.12523
9. Bu XL, Xiang Y, Guo Y. The Role of Iron in Amyotrophic Lateral Sclerosis. Adv. Exp. Med. Biol. 2019; 1173: 145–152.
10. Grad LI, Rouleau GA, Ravits J, et al. Clinical Spectrum of Amyotrophic Lateral Sclerosis (ALS). Cold Spring HarbPerspect Med. 2017; 7(8): a024117. Published 2017 Aug 1. DOI:10.1101/cshperspect.a024117
11. Maria Carmela Tartaglia , Ann Rowe, Karen Findlater, et al. Differentiation between primary lateral sclerosis and amyotrophic lateral sclerosis:examination of symptoms and signs at disease onset and during follow-up. Arch Neurol. 2007 Feb; 64(2): 232-6. DOI: 10.1001/archneur.64.2.232.
12. Brooks BR, Miller RG, Swash M, et al. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord. 2000; 1: 293–299.
13. Forestier NLe, Meininger V. Primary lateral sclerosis: the era of international diagnosis criteria. Rev Neurol (Paris). 2009 May; 165(5): 415-29. DOI: 10.1016/j.neurol.2008.07.022. Epub2008 Oct 7.
14. Foster LA, Salajegheh MK. Motor neuron disease: pathophysiology, diagnosis, and treatment. Am J Med. 2019; 132 (1): 32-37. DOI: 10.1016
15. Fullam T, Statland J. Upper Motor Neuron Disorders: Primary Lateral Sclerosis, Upper Motor Neuron Dominant Amyotrophic Lateral Sclerosis, and Hereditary Spastic Paraplegia. Brain Sci. 2021 May 11; 11(5): 611. DOI: 10.3390/brainsci11050611.
16. Hudson A.J. Amyotrophic lateral sclerosis: Clinical evidence of differences pathogenesis and etiology. Amyotrophic lateral sclerosis: Concepts in Pathogenesis and Etiology. 1990; 108-143.
17. Liewluck T, David S Saperstein. Progressive Muscular Atrophy. Neurol Clin. 2015 Nov; 33(4): 761-73. DOI: 10.1016/j.ncl.2015.07.005.
18. Longinetti E, Fang F. Epidemiology of amyotrophic lateral sclerosis: an update of recent literature. Curr Opin Neurol. 2019; 32(5): 771-776. DOI:10.1097/WCO.0000000000000730
19. Norris F, Shepherd R, Denys E, et al. Onset, natural history and outcome in idiopathic adult motor neuron disease. J Neurol Sci. 1993; 118(1): 48-55. DOI: 10.1016/0022-510x(93)90245-t.
20. Jeffrey M Statland, Richard J Barohn, April L McVey, et al. Patterns of Weakness, Classification of Motor Neuron Disease, and Clinical Diagnosis of Sporadic Amyotrophic Lateral Sclerosis. Neurol Clin. 2015 Nov; 33(4): 735-48. DOI: 10.1016/j.ncl.2015.07.006. Epub 2015 Sep 8.
21. Mitsumoto H, Nagy PL, Gennings C, et al. Phenotypic and molecular analyses of primary lateral sclerosis. Neurol Genet. 2015; 1(1): 3. Published 2015 Apr 14. DOI: 10.1212/01.NXG.0000464294.88607.dd.
22. Statland JM, Barohn RJ, Dimachkie MM, et al. Primary Lateral Sclerosis. NeurolClin. 2015; 33(4): 749-760. DOI:10.1016/j.ncl.2015.07.007.
23. Fournier ChN, Murphy A, Loci L, et al. Primary Lateral Sclerosis and Early Upper Motor Neuron Disease: Characteristics of a Cross-Sectional Population. J Clin Neuromuscul Dis. - 2016 Mar; 17(3): 99-105. DOI: 10.1097/CND.0000000000000102.
24. Meyer T, Münch C, van Landeghem FK, et al. Progressive muscle atrophy. A rarely diagnosed variant of amyotrophic lateral sclerosis. Nervenarzt. 2007; 78(12): 1383-1388. DOI:10.1007/s00115-007-2288-y.
25. Ramanathan RS, Rana S. Demographics and clinical characteristics of primary lateral sclerosis: case series and a review of literature. Neurodegener Dis Manag. 2018; 8(1): 17-23. DOI:10.2217/nmt-2017-0051.
26. Kim WK, Liu X, Sandner J, et al. Study of 962 patients indicates progressive muscular atrophy is a form of ALS. Neurology. 2009; 73(20): 1686-1692. DOI: 10.1212/WNL.0b013e3181c-1dea3.
27. Swash M, Schwartz M. Neuromuscular diseases: a practical approach to diagnosis and management. Springler. New York. 1988; 456.
28. Gordon PH, Cheng B, Katz IB, et al. The natural history of primary lateral sclerosis. Neurology. 2006; 66(5): 647-653. DOI:10.1212/01.wnl.0000200962.94777.71.
29. Bogucki A, Pigońska J, Szadkowska I, et al. Unilateral progressive muscular atrophy with fast symptoms progression. NeurolNeurochir Pol. 2016; 50(1): 52-4. DOI: 10.1016.
30. Marin B, Boumédiene F, Logroscino G, et al. Variation in worldwide incidence of amyotrophic lateral sclerosis: a meta-analysis. Int J Epidemiol. 2017 Feb 1; 46(1): 57-74. doi: 10.1093/ije/dyw061. PMID: 27185810; PMCID: PMC5407171.
31. Wijesekera LC, Leigh PN. Amyotrophic lateral sclerosis Orphanet J.Rare Dis. 2009; Feb. 3: 4:3. DOI: 10.1186/1750-1172-4-3.
Review
For citations:
Davydova T.K., Shadrina S.S., Varlamova M.A., Schneider N.A., Goncharova P.S. Comparative analysis of the duration of sporadic forms of motor neuron disease in the Republic of Sakha (Yakutia). Yakut Medical Journal. 2021;(4):81-86. https://doi.org/10.25789/YMJ.2021.76.19
Views:
20
Email this article 